Monte Rosa Therapeutics

Monte Rosa Therapeutics FCF Growth

The Year-over-Year Free Cash Flow Growth of Monte Rosa Therapeutics (GLUE) as of Oct 18, 2026 is -172.35 %. In the previous year, Year-over-Year Free Cash Flow Growth was 160.48 % — a change of -207.39% (lower).

FCF Growth

-172.35 %

YoY

-207.39%

Last updated:

Year-over-Year Free Cash Flow Growth of Monte Rosa Therapeutics is 2025 -172.35 % . Year-over-Year Free Cash Flow Growth of Monte Rosa Therapeutics was 2024 160.48 % . It decreases by -207.39% lower compared to the previous year.

The Monte Rosa Therapeutics FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2020
-249.85 USD
Jan 1, 2021
-161.31 USD
Jan 1, 2022
-52.51 USD
Jan 1, 2023
40.36 USD
Jan 1, 2024
160.48 USD
Jan 1, 2025
-172.35 USD
The Monte Rosa Therapeutics FCF Growth history
YEARFCF GrowthYoY
-172.35 %-207.39%
160.48 %+297.59%
40.36 %-176.87%
-52.51 %-67.45%
-161.31 %-35.44%
-249.85 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Monte Rosa Therapeutics Stock analysis

What does Monte Rosa Therapeutics do? Monte Rosa Therapeutics Inc, headquartered in Boston, Massachusetts, operates in the Health Care sector within the Biotechnology industry. The company employs 150 full-time employees and went public on June 24, 2021. It focuses on developing precision medicines, particularly molecular glue degraders (MGDs), which selectively target proteins for degradation using the body's natural mechanisms. Monte Rosa has developed a platform called QuEEN (Quantitative and Engineered Elimination of Neosubstrates) to support its MGD discovery and development. Its lead product candidate, MRT-2359, is an orally bioavailable MGD targeting GSPT1 for potential treatment of MYC-driven tumors, including metastatic non-small cell lung cancer and small cell lung cancer. Monte Rosa Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Monte Rosa Therapeutics stock

Year-over-Year Free Cash Flow Growth of Monte Rosa Therapeutics is -172.35 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth Monte Rosa Therapeutics since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's Monte Rosa Therapeutics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Growth — Monte Rosa Therapeutics

Revenue GrowthRevenue CAGR 3YRevenue CAGR 5YRevenue CAGR 10YEarnings GrowthEPS GrowthEBIT GrowthEBIT CAGR 3YEBIT CAGR 5YEBIT CAGR 10YDividend GrowthFCF GrowthBook Value GrowthEarnings CAGR 3YEarnings CAGR 5YEarnings CAGR 10YEPS CAGR 3YEPS CAGR 5YEBITDA Growth YoYEBITDA CAGR 3YEBITDA CAGR 5YGross Profit GrowthOCF Growth YoYEmployee GrowthDividend CAGR 3YDividend CAGR 5YDividend CAGR 10YAsset GrowthEquity GrowthDebt GrowthCapEx GrowthFCF CAGR 3YFCF CAGR 5YMarket Cap GrowthShare Count Growth

All Key Metrics — Monte Rosa Therapeutics